Does the media refer more to VALN or TNYA?

In the previous week, Valneva had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Valneva and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Valneva's score of 0.28 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALT or TNYA?

In the previous week, Altimmune had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Altimmune's score of 0.27 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TNYA or AVTE?

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 485.48%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, TNYA or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is TNYA or AVTE more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Aerovate Therapeutics N/A -90.19% -77.47%

Which has preferable earnings & valuation, TNYA or EIKN?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A

Is TNYA or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Eikon Therapeutics N/A N/A N/A

Does the media favor TNYA or EIKN?

In the previous week, Eikon Therapeutics had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 2 mentions for Tenaya Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Tenaya Therapeutics' score of 0.29 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARVN or TNYA?

In the previous week, Arvinas had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Tenaya Therapeutics. Arvinas' average media sentiment score of 0.76 beat Tenaya Therapeutics' score of 0.29 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenaya Therapeutics (TNYA) Competitors

$0.68 -0.01 (-1.74%)

As of 09/4/2026 04:00 PM Eastern

Compare

TNYA vs. VALN, ALT, AVTE, EIKN, and ARVN

Should you buy Tenaya Therapeutics stock or one of its competitors? Tenaya Therapeutics's main competitors and comparable companies include Valneva (VALN), Altimmune (ALT), Aerovate Therapeutics (AVTE), Eikon Therapeutics (EIKN), and Arvinas (ARVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tenaya Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Valneva currently has a consensus price target of $9.30, indicating a potential upside of 34.98%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 485.48%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

11.4% of Valneva shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valneva has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

Tenaya Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Tenaya Therapeutics' return on equity of -83.75% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

In the previous week, Valneva had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Valneva and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Valneva's score of 0.28 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.31	-$130.33M	-$2.11	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Summary

Tenaya Therapeutics beats Valneva on 12 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Altimmune?

Altimmune (NASDAQ:ALT) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Altimmune has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Altimmune had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Altimmune's score of 0.27 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-31.41%	-26.96%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Altimmune has higher revenue and earnings than Tenaya Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$31K	21,459.73	-$88.09M	-$0.78	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Altimmune currently has a consensus target price of $14.33, suggesting a potential upside of 319.10%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 485.48%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Tenaya Therapeutics beats Altimmune on 10 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 485.48%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for Aerovate Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Aerovate Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Tenaya Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tenaya Therapeutics beats Aerovate Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Tenaya Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 485.48%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 130.20%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tenaya Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, Eikon Therapeutics had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 2 mentions for Tenaya Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Tenaya Therapeutics' score of 0.29 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Eikon Therapeutics	N/A	N/A	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Tenaya Therapeutics beats Eikon Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Arvinas had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Tenaya Therapeutics. Arvinas' average media sentiment score of 0.76 beat Tenaya Therapeutics' score of 0.29 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 50.87%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 485.48%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Arvinas has a net margin of 2.94% compared to Tenaya Therapeutics' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Arvinas has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$316.70M	1.91	-$80.80M	$0.10	93.90
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arvinas has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

Summary

Arvinas beats Tenaya Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$155.91M	$4.02B	$7.26B	$12.90B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-1.29	12.71	273.83	25.45
Price / Sales	N/A	1,310.70	608.03	79.09
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	2.20	16.15	12.85	6.17
Net Income	-$90.60M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-1.00%	0.31%	1.04%	-0.14%
1 Month Performance	-12.93%	8.25%	5.52%	1.02%
1 Year Performance	-49.39%	49.17%	24.39%	14.51%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.1294 of 5 stars	$0.68 -1.7%	$4.00 +485.5%	-44.9%	$155.91M	N/A	N/A	110
VALN Valneva	2.0715 of 5 stars	$6.30 -2.0%	$9.30 +47.6%	-22.1%	$610.11M	$197.56M	N/A	700	Gap Down
ALT Altimmune	2.3676 of 5 stars	$3.11 flat	$14.33 +360.9%	-3.9%	$604.95M	$40K	N/A	50
AVTE Aerovate Therapeutics	N/A	$20.84 -2.1%	N/A	+164.8%	$604.05M	N/A	N/A	20	High Trading Volume
EIKN Eikon Therapeutics	3.696 of 5 stars	$10.46 -4.7%	$25.00 +139.0%	N/A	$594.73M	N/A	N/A	384	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. VALN, ALT, AVTE, EIKN, and ARVN

How does Tenaya Therapeutics compare to Valneva?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Summary

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Summary

How does Tenaya Therapeutics compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. VALN, ALT, AVTE, EIKN, and ARVN

How does Tenaya Therapeutics compare to Valneva?

Do analysts prefer VALN or TNYA?

Do insiders and institutionals have more ownership in VALN or TNYA?

Which has more volatility and risk, VALN or TNYA?

Is VALN or TNYA more profitable?

Does the media refer more to VALN or TNYA?

Which has preferable earnings & valuation, VALN or TNYA?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Which has more volatility and risk, ALT or TNYA?

Do insiders and institutionals hold more shares of ALT or TNYA?

Does the media refer more to ALT or TNYA?

Is ALT or TNYA more profitable?

Which has higher valuation & earnings, ALT or TNYA?

Do analysts rate ALT or TNYA?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Do analysts rate TNYA or AVTE?

Does the media prefer TNYA or AVTE?

Which has higher valuation and earnings, TNYA or AVTE?

Is TNYA or AVTE more profitable?

Which has more volatility and risk, TNYA or AVTE?

Do insiders & institutionals have more ownership in TNYA or AVTE?

Summary

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Do analysts rate TNYA or EIKN?

Which has preferable earnings & valuation, TNYA or EIKN?

Does the media favor TNYA or EIKN?

Is TNYA or EIKN more profitable?

Do institutionals and insiders have more ownership in TNYA or EIKN?

Summary

How does Tenaya Therapeutics compare to Arvinas?

Does the media refer more to ARVN or TNYA?

Do analysts recommend ARVN or TNYA?

Is ARVN or TNYA more profitable?

Which has stronger earnings & valuation, ARVN or TNYA?

Do institutionals and insiders hold more shares of ARVN or TNYA?

Which has more volatility & risk, ARVN or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools